🔴 GT Biopharma is trading 13% down with no clear catalyst

GT Biopharma is trading 12.86% lower at $6.37 on October 21, 2026; no clear company-specific catalyst has been identified.

• The investor-relations page lists a September 15 announcement as the company’s latest news. An October 21 Form 4 does not provide evidence of a price-moving event.
• The decline sharply contrasts with the supplied biotech-sector trend: XBI is up 2.10%. Available evidence does not establish a cause, and the move remains unexplained.